Administrative claims studies do not adequately distinguish pulmonary arterial hypertension (PAH) from other forms of pulmonary hypertension (PH). Our aim is to develop and validate a set of algorithms using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes and electronic medical records (EMR), to identify patients with PAH. From January 2012 to Au...

The binding of labeled carcinogens [3H]benzo(a)pyrene [3H]dibenz(a,/i)anthracene, and [3H]dibenz(a,c)anthracene to nuclear chromatin was examined in AKR mouse embryo cells grown in culture. The influence of unlabeled weakly and strongly carcinogenic polycyclic aromatic hydrocar bons (PAH) and the metabolic inhibitor 7,8-benzoflavone on the binding of labeled PAH to nuclear chromatin was examine...

Pulmonary arterial hypertension (PAH) is a progressive disease characterized by vascular remodeling of pulmonary arteries (PAs) and increased vascular resistance in the lung. Monocrotaline (MCT), a toxic alkaloid, is widely used for developing rat models of PAH caused by injury to pulmonary endothelial cells; however, characteristics of vascular functions in MCT-induced PAH vary and are not ful...

Tetrahydrobiopterin (BH4)-responsive phenylalanine hydroxylase (PAH) deficiency is a recently recognized variant of phenylketonuria, with a probable multifactorial molecular basis. In this study we have investigated the effect of BH4 on PAH gene expression in human hepatoma. Our results show that increased BH4 levels result in an enhancement of PAH activity and PAH protein, due to longer turnov...

Background Pulmonary arterial hypertension (PAH) associated with connective tissue diseases (CTD) (CTD-PAH) remains a difficult challenge in clinical practice. We aimed to evaluate the effects of targeted vasodilators patients severe CTD-PAH. Methods The data 53 CTD-PAH hospitalized at Department Rheumatology and Immunology, Affiliated Drum Tower Hospital Nanjing University Medical School, were...

Pulmonary arterial hypertension (PAH) is an entity that is known to complicate connective tissue diseases (CTD). PAH in CTD is a very important diagnosis which greatly affects treatment and prognosis. The most commonly affected CTD is scleroderma, although lupus, inflammatory myopathies such as poly and dermatomyositis, and mixed CTD are also associated with PAH. The manifestations of PAH have ...

Pulmonary arterial hypertension (PAH) is a rare, progressive disorder that leads to an inexorable rise in pulmonary vascular resistance, ultimately resulting in right ventricular failure and death if left untreated. Currently available pulmonary vasoremodeling therapy has significantly improved morbidity and mortality in PAH. However, 3-year mortality in PAH is still higher than in many other c...

Polycyclic aromatic hydrocarbons (PAH) were measured in sediment cores from 13 locations in South-Western Barents Sea as part of a detailed study of the Norwegian seabed under the MAREANO program. The generally low PAH levels found, an average around 200 ng g(-1) dry weight for sum PAH, indicate low inputs of petroleum hydrocarbons to the marine environment in the area. Differences in PAH compo...

Phytoremediation offers an ecologically and economically attractive remediation technique for soils contaminated with polycyclic aromatic hydrocarbons (PAHs). In addition to the choice of plant species, agronomic practices may affect the efficiency of PAH phytoremediation. Inorganic nutrient amendments may stimulate plant and microbial growth, and clipping aboveground biomass might stimulate ro...